It was a sheer pleasure to have @AdamSharpMedOnc here in Minnesota delivering a Cancer Center Seminar lecture about manipulation of the apoptosis pathway for prostate cancer therapeutics. Thanks @scottdehm for inviting and hosting him. Let the collaborations begin! @UMNCancer

Can anyone top the Halabi model for predicting survival in mCRPC? Yes! Dr Halabi does it again! See our ctDNA based clinical-genetic model in first line ARPI treatment out today in @EUplatinum: https://t.co/OOeFavZgG8 @scottdehm @DukeGUCancer @DukeCancer @PCFnews

Fascinating work by Chen et al in uncovering new metabolomics of SPOP-mutant prostate cancer, we review here @EAntonarakis @scottdehm https://t.co/h1esACPGDs

Check out our new work exploring AR biology in advanced prostate cancer: https://t.co/SqZKXZ8kcR. We found that tumours expressing a specific AR variant (ARv567es) have a distinct transcriptomic profile and are resistant to androgen deprivation and bipolar androgen therapy

🧪 Dr. @scottdehm and collaborators including @huang_lab, @EAntonarakis, & @mishabeltran showed that double-negative #CRPC cells express genes defining basal, club, and hillock epithelial cells from benign #prostate. @PNASNews | https://t.co/9cG13JCvXe

@UMNCancer @UMN_GradSchool This study benefitted from tremendous collaborations with @huang_lab @EAntonarakis @mishabeltran @JoshLangMD @AttardLab and many others!

This work was led by a talented graduate student (Sam Pitzen) @umncancer @UMN_GradSchool who will soon be defending his PhD thesis (and entering the job market).

KLF5 was identified as the transcription factor that supports these transcriptional features. Defining DNPC by what "it is" (a hybrid basal/club/hillock phenotype), instead of what "it's not" (negative for AR and neuroendocrine features) may aid development of new therapies.

We found that the double-negative phenotype of castration-resistant prostate cancer (a.k.a. "DNPC") exhibits the same transcriptional features that define basal, club, and hillock epithelial cells of the benign prostate.

Check out our latest study! Comparative transcriptomics reveals a mixed basal, club, and hillock epithelial cell identity in castration-resistant prostate cancer | PNAS

Thrilled to share a project that we envisioned over a decade ago to perform high purity/high specificity molecular analysis of circulating tumor cells! Led by the brilliant @marina_sharifi and @JSperger @AACR Funded by @PCF_Science @NIH @CDMRP

Excited to share a new paper by postdoc Dr. Kiel Tietz @UMNCancer! CPSF1 inhibition promotes widespread use of intergenic polyadenylation sites and impairs glycolysis in prostate cancer cells: Cell Reports https://t.co/ZuQxX2ISOX Work funded by @CDMRP and @NCICancerBio

In memory of Dr. Felix Feng. Thank you @EUplatinum for honoring our beloved colleague and friend, gone too soon. We miss you Felix @MaryFengMD @nlinmd @PCF_Science https://t.co/WOGllHwEfQ

The two faces of FOXA1 muts in PCa. Congrats to Justin Hwang for this revised classification of FOXA1 alts in PCa. Different FOXA1 classes have different biologic behaviors, clinical outcomes & racial clustering, esp. Class 1B and 2. @UMNcancer @scottdehm https://t.co/oYP4oN6oHx

PROSTATE Paper 2 Franseschini et al. developed a targeted DNA methylation assay for the detection of neuroendocrine prostate cancer using plasma cell-free DNA with an AUC > 0.93. Their assay also quantifies tumor content and offers a phenotype evidence score, which reflects

It is this time of the Year again: 10 TOP TRANSLATIONAL PAPERS IN GU ONCOLOGY! 1/ Prostate Paper 1 Fonseca et al. introduced a machine-learning approach that predicts whether patients with #mCRPC have sufficient ctDNA% for informative genotyping. This study addresses a critical

PROSTATE Paper 3 Knutson et al. developed the AR-ctDETECT assay to detect ctDNA in limiting plasma cfDNA from pts w/ #mCRPC in @ALLIANCE_org A031201 ph3 trial of enzalutamide w/ or w/o abiraterone. The ctDNA assay was able to prognosticate outcomes, as pts w/ mCRPC who were

AR alterations inform circulating tumor DNA detection in metastatic castration resistant prostate cancer patients out in Nature Communications https://t.co/19CWA6V5PL This study introduces a custom circulating tumor DNA (ctDNA) 🧬sequencing assay, AR-ctDETECT, designed to

@AarmstrongDuke @DukeCancer @DukeGUCancer @theNCI @PCFnews We thank all the contributors to this collaborative study! @UMNCancer @mishabeltran @charlesryanmd @EAntonarakis @lukegaughan22

This study was a collaboration initiated with @AarmstrongDuke and Susan Halabi @DukeCancer @DukeGUCancer and was funded by @theNCI and @PCFnews!